Nanotherapy Delivers Tapeworm Drug to Endometriosis Cells in Mouse Trial
Researchers at Washington State University have developed a nanotherapy that delivers the anti-parasitic drug niclosamide directly to immune cells associated with endometriosis. In mouse models, this approach reduced lesion growth and pain symptoms after a single dose, offering a potential non-hormonal alternative to current treatments. The study addresses the limitations of oral niclosamide, which has poor solubility and causes side effects, by using a dendrimer nanocarrier to target specific macrophages. While promising, the therapy remains in the preclinical stage, with human trials and FDA approval potentially taking five years or more.
